Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.3.2049

Single Nucleotide Polymorphisms in the NER Pathway and Clinical Outcome of Patients with Bone Malignant Tumor  

Sun, Xiao-Hui (Department of Orthopaedics, the First Affiliated Hospital of Xinxiang Medical University)
Hou, Wen-Gen (Department of Orthopaedics, the First Affiliated Hospital of Xinxiang Medical University)
Zhao, Hong-Xing (Department of Orthopaedics, the First Affiliated Hospital of Xinxiang Medical University)
Zhao, Yi-Lei (Department of Orthopaedics, the First Affiliated Hospital of Xinxiang Medical University)
Ma, Chao (Department of Orthopaedics, the First Affiliated Hospital of Xinxiang Medical University)
Liu, Ying (Department of Orthopaedics, the First Affiliated Hospital of Xinxiang Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.3, 2013 , pp. 2049-2052 More about this Journal
Abstract
The effects of polymorphisms in ERCC5, ERCC6, XPC, CCNH and MMS19L on osteosarcoma response to chemotherapy and the survival of the affected patients were assessed. Genotyping of ERCC5, ERCC6, XPC, CCNH and MMS19L was performed by PCR-RFLP assay. The median PFS was 12.8 months, and the median OS was 18.6 months. Individuals carrying homozygous genotypes of ERCC5 rs17655 and ERCC5 rs1047768 were more like to have good response to treatment, while those carrying homozygous genotypes of MMS19L rs29001322 showed poor response. Osteosarcoma patients carrying TT genotype of ERCC5 rs1047768 showed a significantly longer PFS (16.8 months) and OS (21.4 months) than CC genotype, with HRs(95% CI) of 0.31 (0.10-0.93) and 0.32 (0.06-0.97), respectively. Conversely, those with the TT genotype of MMS19L rs29001322 demonstrated shorter PFS and OS, the HRs (95% CI) being 2.23 (1.08-4.15) and 4.62 (1.45-16.08), respectively. Our findings showed polymorphisms in ERCC5 rs1047768 and MMS19L rs29001322 to be associated with clinical outcome of osteosarcoma patients undergoing chemotherapy.
Keywords
Single Nucleotide polymorphisms; osteosarcoma; chemotherapy; clinical outcome;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Biason P, Hattinger CM, Innocenti F, et al (2012). Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy. Pharmacogenomics J, 12, 476-83.   DOI   ScienceOn
2 Caronia D, Patiño-García A, Milne RL, et al (2009). Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J, 9, 347-53.   DOI   ScienceOn
3 Chou AJ, Gorlick R (2006) Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther, 6, 1075-85.   DOI   ScienceOn
4 Dogan M, Karabulut HG, Tukun A, et al (2012). Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients. Asian Pac J Cancer Prev, 13, 1553-6.   과학기술학회마을   DOI   ScienceOn
5 Goode EL, Ulrich CM, Potter JD (2002). Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev, 11, 1513-30.
6 Le MV, Longy M, Bonaiti-Pellie C, et al (2006). Genetic polymorphisms of the XPG and XPD nucleotide excision repair genes in sarcoma patients. Int J Cancer, 119, 1732-5.   DOI   ScienceOn
7 Hatfield MD, Reis AM, Obeso D, et al (2006). Identification of MMS19 domains with distinct functions in NER and transcription. DNA Repair (Amst), 5, 914-24.   DOI   ScienceOn
8 Hattinger CM, Pasello M, Ferrari S, et al (2010). Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs, 15, 615-34.   DOI   ScienceOn
9 Koeppel F, Poindessous V, Lazar V, et al (2004). Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells. Clin Cancer Res, 10, 5604-13.   DOI   ScienceOn
10 Liu D, Wu HZ, Zhang YN, et al (2012). DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy. Mol Carcinog, 51, E83-93.   DOI   ScienceOn
11 Martin LP, Hamilton TC, Schilder RJ (2008). Platinum resistance: the role of DNA repair pathways. Clin Cancer Res, 14, 1291-5.   DOI   ScienceOn
12 Massuti B, Cobo M, Camps C, et al (2012). Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. Lung Cancer, 76, 354-61.   DOI   ScienceOn
13 McWilliams RR, Bamlet WR, de Andrade M, et al (2009). Nucleotide excision repair pathway polymorphisms and pancreatic cancer risk: evidence for role of MMS19L. Cancer Epidemiol Biomarkers Prev, 18, 1295-302.   DOI   ScienceOn
14 Ott K, Rachakonda PS, Panzram B, et al (2011). DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. Ann Surg Oncol, 18, 2688-98.   DOI   ScienceOn
15 Reed E (1998). Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev, 24, 331-44.   DOI   ScienceOn
16 Schöffski P, Taron M, Jimeno J, et al (2011). Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur J Cancer, 47, 1006-12.   DOI   ScienceOn
17 Stoehlmacher J, Park DJ, Zhang W, et al (2004). A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer, 91, 344-54.
18 Zhang L, Gao G, Li X, et al (2012). Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy. PLoS One, 7, e48350.   DOI
19 Zhou SF, Di YM, Chan E, et al (2008) Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab, 9, 738-84.   DOI   ScienceOn